COVID19- clinical presentation and therapeutic considerations

Virology, 1968, Coronaviruses, Nature, 220, 650, 10.1038/220650b0 N, 2020, Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003 Elsevier Connect , the company ’ s public news and information, Lancet, 362, 1353 Zaki, 2012, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med., 367, 1814, 10.1056/NEJMoa1211721 Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Meyerowitz, 2020, Towards an accurate and systematic characterization of persistently asymptomatic infection with SARS-CoV-2, SSRN Electron J, 280, 717 Jin, 2020, Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms, Gut, 69, 1002, 10.1136/gutjnl-2020-320926 Stokes, 2020, Coronavirus disease 2019 case surveillance — United States, january 22–may 30, 2020, MMWR Morb. Mortal. Wkly. Rep., 69, 759, 10.15585/mmwr.mm6924e2 Walker, 2020, Anosmia and loss of smell in the era of covid-19, BMJ, 370, 1 Lan, 2020, COVID-19 symptoms predictive of healthcare workers’ SARS-CoV-2 PCR results, PloS One, 15, 1, 10.1371/journal.pone.0235460 Kirschenbaum, 2020, Inflammatory olfactory neuropathy in two patients with COVID-19, Lancet, 396, 166, 10.1016/S0140-6736(20)31525-7 Docherty, 2020, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ, 369, 1 Wölfel, 2020, Virological assessment of hospitalized patients with COVID-2019, Nature, 581, 465, 10.1038/s41586-020-2196-x Carsana, 2020, 19 Lucas, 2020, Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature, 584 Mathew, 2020, Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications, Science, 1209 Chen, 2020, T cell responses in patients with COVID-19, Nat. Rev. Immunol., 20, 529, 10.1038/s41577-020-0402-6 Takahashi, 2020, Sex differences in immune responses that underlie COVID-19 disease outcomes, Nature, published online Aug 26 Helms, 2020, High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med [Internet], 46, 1089, 10.1007/s00134-020-06062-x Poissy, 2020, Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence, Circulation, 184, 10.1161/CIRCULATIONAHA.120.047430 Bellosta, 2020, Acute limb ischemia in patients with COVID-19 pneumonia, J. Vasc. Surg., 10.1016/j.jvs.2020.04.483 Ackermann, 2020, Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19, N. Engl. J. Med., 383, 120, 10.1056/NEJMoa2015432 Rasmussen, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5 Dweck, 2020, Global evaluation of echocardiography in patients with COVID-19, Eur Hear J - Cardiovasc Imaging, 949, 10.1093/ehjci/jeaa178 Puntmann, 2020, Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19), JAMA Cardiol, 1 Lindner, 2020, Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases, JAMA Cardiol, 10.1001/jamacardio.2020.3551 Baldi, 2020, Out-of-Hospital cardiac arrest during the covid-19 outbreak in Italy, N. Engl. J. Med., 383, 494, 10.1056/NEJMc2010418 Lai, 2020, Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in New York city, JAMA Cardiol., 5, 1154, 10.1001/jamacardio.2020.2488 Mao, 2020, Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China, JAMA Neurol, 77, 683, 10.1001/jamaneurol.2020.1127 Belani, 2020, COVID-19 is an independent risk factor for acute ischemic stroke, Am. J. Neuroradiol., 1361, 10.3174/ajnr.A6650 Gupta, 2020, Extrapulmonary manifestations of COVID-19, Nat. Med., 26, 1017, 10.1038/s41591-020-0968-3 Iadecola, 2020, Effects of COVID-19 on the nervous system, Cell, 1 Schünemann, 2020, Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19, Ann. Intern. Med., 173, 10.7326/M20-2306 Coppo, 2020, Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study, Lancet Respir Med, 8, 765, 10.1016/S2213-2600(20)30268-X Williamson, 2020, Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, bioRxiv Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet (London, England), 395, 1569, 10.1016/S0140-6736(20)31022-9 Beigel, 2020, Remdesivir for the treatment of covid-19 — preliminary report, N. Engl. J. Med., 1–12 Spinner, 2020, Effect of remdesivir vs standard care on clinical status at 11 Days in patients with moderate COVID-19: a randomized clinical trial, Jama, 94404 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents [Internet], 56, 105949, 10.1016/j.ijantimicag.2020.105949 Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on Hydroxychloroquine, 5 June 2020 No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19 [Internet]. [cited 2020 Aug 30]. Available from: https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf. Cavalcanti, 2020, Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19, N. Engl. J. Med., 10.1056/NEJMoa2019014 Boulware, 2020, A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19, N. Engl. J. Med., 383, 517, 10.1056/NEJMoa2016638 Blanco-Melo, 2020, Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell, 181, 1036, 10.1016/j.cell.2020.04.026 Park, 2020, Type I and type III interferons – induction, signaling, evasion, and application to combat COVID-19, Cell Host Microbe, 27, 870, 10.1016/j.chom.2020.05.008 Mantlo, 2020, Antiviral activities of type I interferons to SARS-CoV-2 infection, Antivir. Res., 179, 104811, 10.1016/j.antiviral.2020.104811 Hung, 2020, Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet [Internet], 395 Zhou, 2020, Interferon-α2b treatment for COVID-19, Front. Immunol., 11, 1 Synairgen Announces Positive Results from Trial of SNG001 in Hospitalised COVID-19 Patients. [Internet]. [cited 2020 Nov 5]. Available from: https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf. Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, N. Engl. J. Med., 382, 1787, 10.1056/NEJMoa2001282 Chen, 2020 2020, Dexamethasone in hospitalized patients with covid-19 — preliminary report, N. Engl. J. Med. Angus, 2020, Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial, Jama, 15261 Sterne, 2020, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, Jama, 1 McCarthy, 2020, Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state, Respirology, 2019 Guaraldi, 2020, Tocilizumab in patients with severe COVID-19: a retrospective cohort study, Lancet Rheumatol Roche Provides an Update on the Phase III COVACTA Trial of Actemra/RoActemra in Hospitalised Patients with Severe COVID-19 Associated Pneumonia [Internet]. [cited 2020 Aug 30]. Available from:: https://www.roche.com/investors/updates/inv-update-2020-07-29.htm. Cotter, 2020, The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: a structured summary of a study protocol for a randomised controlled trial, Trials, 21, 20, 10.1186/s13063-020-04680-w Casadevall, 2004, Passive antibody therapy for infectious diseases, Nat. Rev. Microbiol., 2, 695, 10.1038/nrmicro974 Mair-Jenkins, 2015, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J. Infect. Dis., 211, 80, 10.1093/infdis/jiu396 Mulangu, 2019, A randomized, controlled trial of Ebola virus disease therapeutics, N. Engl. J. Med., 381, 2293, 10.1056/NEJMoa1910993 1997, Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus, J Infect Dis, 176, 1215, 10.1086/514115 Joyner, 2020, Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience, medRxiv Li, 2020, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, J. Am. Med. Assoc., 324, 460, 10.1001/jama.2020.10044 Joyner, 2020, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients, Mayo Clin. Proc., 95, 1888, 10.1016/j.mayocp.2020.06.028 Covid-19 Biologics Tracker Hansen, 2020, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science 80-, 1014 REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements [Internet]. [cited 2020 Nov 5]. Available from: https://investor.regeneron.com/news-releases/news-release-details/regn-cov2-independent-data-monitoring-committee-recommends. Pinto, 2020, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, 583, 10.1038/s41586-020-2349-y Lang, 2020, GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches, Nat. Rev. Immunol., 20, 507, 10.1038/s41577-020-0357-7 Walz, 2020, Janus kinase-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis, medRxiv, 1101